Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

828
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
828
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

180
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
180
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

142
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
142
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

729
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
729
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

481
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

[Guide to the application of the 9th TNM classification for lung cancer : Statement/position paper of the Thoracic Pathology Working Group].

Pathologie (Heidelberg, Germany)·2025
Same author

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren.

Hamostaseologie·2024
Same author

New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline.

Neurological research and practice·2024
Same author

Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism. The revised AWMF S2k Guideline

VASA. Zeitschrift fur Gefasskrankheiten·2023
Same author

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Related Experiment Video

Updated: Jul 14, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

[Basics for the Use of Andexanet].

J Koscielny1, I Birschmann2, R Bauersachs3,4

  • 1Charité, Universitätsmedizin Berlin, Gerinnungsambulanz mit Hämophiliezentrum, Berlin, Germany.

Hamostaseologie
|October 9, 2023
PubMed
Summary

For severe bleeding associated with direct oral anticoagulants, specific reversal agents like andexanet are available. Prompt resumption of anticoagulation after hemostasis is crucial, balancing bleeding and thromboembolic risks.

More Related Videos

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

21.7K
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

9.9K

Related Experiment Videos

Last Updated: Jul 14, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

21.7K
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

9.9K

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Context:

  • Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban are widely used for anticoagulation.
  • Life-threatening bleeding can occur in patients taking DOACs.
  • Reversal agents such as andexanet are available for specific DOACs.

Purpose:

  • To provide evidence-based recommendations for managing severe bleeding in patients on DOACs.
  • To guide the appropriate use of reversal agents like andexanet.
  • To facilitate prompt and safe resumption of anticoagulation after bleeding events.

Summary:

  • Severe bleeding in patients on DOACs necessitates consideration of reversal agents, particularly in cases of life-threatening hemorrhage, intracranial bleeding, or unstoppable gastrointestinal bleeding.
  • Andexanet is indicated for reversal of anticoagulation in patients treated with rivaroxaban or apixaban experiencing severe bleeding.
  • Following successful hemostasis, anticoagulation should be resumed promptly, carefully weighing the patient's individual risks of bleeding and thrombosis.

Impact:

  • Improved management of bleeding emergencies in patients on DOACs.
  • Standardized approach to the use of reversal agents, enhancing patient safety.
  • Facilitation of interdisciplinary collaboration for optimal patient care during anticoagulation-related bleeding events.